License and Collaborative Agreements (Details) (USD $)	1 Months Ended		3 Months Ended		6 Months Ended
	Jan. 31, 2010	Jan. 31, 2006	Jun. 30, 2013	Jun. 30, 2012	Jun. 30, 2013	Jun. 30, 2012
Taiho Pharmaceutical Co., Ltd. [Member] | Minimum [Member]
License and Collaborative Agreements [Line Items]
Revenue recognized					$ 955,000
Hitachi Chemical Co., Ltd. [Member] | Collaborative Arrangement [Member]
License and Collaborative Agreements [Line Items]
Revenue recognized			0	149,175	0	235,095
Collaborative agreement, automatic renewal period					1 year
Licensing Agreements [Member] | University of Southern California [Member]
License and Collaborative Agreements [Line Items]
Royalty expense included in cost of revenue			86,908	75,938	191,014	132,440
Licensing Agreements [Member] | Roche Molecular Systems [Member]
License and Collaborative Agreements [Line Items]
Royalty expense included in cost of revenue			84,362	80,418	174,507	143,887
Licensing Agreements [Member] | Glaxo, Smith, Kline [Member]
License and Collaborative Agreements [Line Items]
Milestone payment received					500,000
Service Agreements [Member] | Taiho Pharmaceutical Co., Ltd. [Member]
License and Collaborative Agreements [Line Items]
Revenue recognized			306,260	292,675	340,180	536,800
Service Agreements [Member] | GlaxoSmithKline, LLC [Member]
License and Collaborative Agreements [Line Items]
Revenue recognized			2,814	145,100	2,814	222,577
Revenue deferred	1,300,000	2,000,000
Collaborative agreement, optional additional period					1 year
Collaborative agreement, term					2 years
Service Agreements [Member] | GSK Bio [Member]
License and Collaborative Agreements [Line Items]
Revenue recognized			$ 1,176,361	$ 90,817	$ 2,532,745	$ 732,428
Collaborative agreement, termination notice period					90 days